ACW announces results of pivotal Alzheimer’s trial
ACW has announced topline results from its pivotal, placebo-controlled XanaMIA trial of oral emestedastat (Xanamem®) over 36 weeks of treatment in 247 patients with mild to moderate Alzheimer’s disease and elevated levels of the pTau181 blood biomarker.
View announcement
2026 AGM - Letter to Shareholders, Notice of AGM & Proxy Form
ACW has issued documents for its Annual General Meeting to be held on Monday 30 November 2026 at 10am. This will be a hybrid meeting to be held in Sydney and online. Shareholders should check emails or post (depeding on preferences) for details and proxy voting instructions.
View AGM details and documents on the ACW InvestorHub
View announcement
ACW receives $10.8m R&D tax incentive rebate from the ATO
Actionogen has received a research and development tax incentive (RDTI) rebate of $10.8m from the ATO for the 2026 financial year.
After repaying loans advanced against this FY26 RDTI, the net proceeds received were ~$6.0m.
View announcement
ACW pivotal Alzheimers trial database lock - results mid-Nov
Actinogen has announced formal achievement of the ‘database lock’ milestone in its XanaMIA phase 2b/3 Alzheimer’s disease trial. Guidance for trial topline final results readout has been narrowed to mid-November this year.
View announcement
ACW September 2026 quarterly activity report & Appendix 4C
Actinogen has released its quarterly activity report and Appendix 4C for the three-month period ended 30 September 2026.
View announcement
XanaMIA pivotal Alzheimer's disease trial completes final patient visit
Actinogen has announced that the final trial participant visit has been completed in its XanaMIA phase 2b/3 Alzheimer’s disease clinical trial. The topline final results readout for the trial remains on track for November this year.
View announcement